Onward Medical N.V. (ONWD.BR)
EUR 4.74
(-0.21%)
EUR 4.74
(-0.21%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 16.87 Million EUR | 17.37% |
| 2022 | 14.37 Million EUR | 5.21% |
| 2021 | 13.66 Million EUR | -67.48% |
| 2020 | 42.01 Million EUR | 24.29% |
| 2019 | 33.8 Million EUR | 92.47% |
| 2018 | 17.56 Million EUR | 64.71% |
| 2017 | 10.66 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 17.31 Million EUR | 8.06% |
| 2024 Q1 | 16.02 Million EUR | -5.05% |
| 2023 Q4 | 16.87 Million EUR | 3.48% |
| 2023 Q1 | 15.36 Million EUR | 6.89% |
| 2023 FY | 16.87 Million EUR | 17.37% |
| 2023 Q3 | 16.3 Million EUR | 2.86% |
| 2023 Q2 | 15.85 Million EUR | 3.16% |
| 2022 Q3 | 13.95 Million EUR | -0.21% |
| 2022 Q2 | 13.98 Million EUR | 3.1% |
| 2022 Q4 | 14.37 Million EUR | 3.06% |
| 2022 Q1 | 13.55 Million EUR | -0.78% |
| 2022 FY | 14.37 Million EUR | 5.21% |
| 2021 Q4 | 13.66 Million EUR | 3.59% |
| 2021 FY | 13.66 Million EUR | -67.48% |
| 2021 Q3 | 13.19 Million EUR | -81.0% |
| 2021 Q2 | 69.44 Million EUR | 0.19% |
| 2021 Q1 | 69.31 Million EUR | 64.97% |
| 2020 Q4 | 42.01 Million EUR | 0.33% |
| 2020 Q3 | 41.87 Million EUR | 0.0% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 FY | 42.01 Million EUR | 24.29% |
| 2019 FY | 33.8 Million EUR | 92.47% |
| 2018 FY | 17.56 Million EUR | 64.71% |
| 2017 FY | 10.66 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -397.758% |
| ABIVAX Société Anonyme | 55.46 Million EUR | 69.577% |
| Adocia SA | 13.08 Million EUR | -28.927% |
| Aelis Farma SA | 4.03 Million EUR | -317.88% |
| Biophytis S.A. | 8.27 Million EUR | -104.039% |
| Advicenne S.A. | 17.42 Million EUR | 3.162% |
| genOway Société anonyme | 7.23 Million EUR | -133.279% |
| IntegraGen SA | 1.12 Million EUR | -1400.265% |
| Medesis Pharma S.A. | 1.2 Million EUR | -1306.167% |
| Neovacs S.A. | 650 Thousand EUR | -2496.0% |
| NFL Biosciences SA | 62.17 Thousand EUR | -27039.962% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -287.328% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -521.089% |
| Sensorion SA | 2.86 Million EUR | -488.193% |
| Theranexus Société Anonyme | 3.64 Million EUR | -363.187% |
| TME Pharma N.V. | 1.16 Million EUR | -1347.17% |
| Valbiotis SA | 6.87 Million EUR | -145.333% |
| TheraVet SA | 1.15 Million EUR | -1354.822% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -87.531% |
| argenx SE | 18.1 Million EUR | 6.801% |
| BioSenic S.A. | 28.16 Million EUR | 40.08% |
| Celyad Oncology SA | 902 Thousand EUR | -1770.732% |
| DBV Technologies S.A. | 13.01 Million USD | -29.615% |
| Galapagos NV | 9.59 Million EUR | -75.844% |
| Genfit S.A. | 70.17 Million EUR | 75.955% |
| GeNeuro SA | 7.73 Million EUR | -118.072% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -218.738% |
| Innate Pharma S.A. | 39.89 Million EUR | 57.702% |
| Inventiva S.A. | 37.4 Million EUR | 54.891% |
| MaaT Pharma SA | 14.07 Million EUR | -19.886% |
| MedinCell S.A. | 58.96 Million EUR | 71.381% |
| Nanobiotix S.A. | 50.56 Million EUR | 66.629% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -23.283% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | 63.158% |
| Oxurion NV | 12.33 Million EUR | -36.809% |
| Pharming Group N.V. | 155.29 Million EUR | 89.134% |
| Poxel S.A. | 46.9 Million EUR | 64.021% |
| GenSight Biologics S.A. | 18.42 Million EUR | 8.433% |
| Transgene SA | 1.25 Million EUR | -1242.403% |
| Financière de Tubize SA | 79.2 Million EUR | 78.694% |
| UCB SA | 3.03 Billion EUR | 99.445% |
| Valneva SE | 208.81 Million EUR | 91.919% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -44305.263% |